CBD

Canopy Growth Announces Completion Of Study On The Long-Term Effects Of CBD

The study specifically focused on toxicity and lifespan effects of CBD

Canopy Growth Corporation and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.

The study was commissioned to evaluate the solubility, stability, acute toxicity, thermotolerance, and effects on lifespan of CBD in C. elegans as part of Canopy Growth’s ongoing commitment to provide the data required to support and influence public policy through research. To the best of the Company’s knowledge, this study represents the first long-term toxicity and lifespan research regarding the effects of chronic exposure to cannabidiol – one of the cannabinoids found in cannabis.

Acute and long-term exposure studies of CBD at physiologically relevant concentrations were studied in the worm model Caenorhabditis elegans (C. elegans) on the basis that 60-80% of their genes are shared with humans, and their comparatively short lifespan of 2-3 weeks makes such studies feasible. In the C. elegans model, which is recognized as a valid model for this kind of research, CBD did not demonstrate any degree of acute or life-long toxicity or related liabilities at physiological concentrations. Instead, CBD extended mean lifespan up to 18% and increased late-stage life activity by up to 206% compared to the untreated controls within the study.

“Despite widespread use of CBD, no life-long toxicity studies had been conducted to date to determine the impact – or potential impact – of long-term exposure to CBD,” shared Hunter Land, Senior Director of Translational and Discovery Science at Canopy Growth. “These results serve as the only CBD life-long exposure data in an in vivo model to date, and the absence of long-term toxicity gives us the evidence we need as an industry to continue researching the potential health benefits for the broader application of CBD.”

The study was conducted in partnership with NemaLife Inc., and is published in Cannabis and Cannabinoid Research journal and available online.

While further research into the life-long use of CBD should be carried out in mammalian models, the C. elegans model indicates a lack of long-term toxicity at physiologically relevant concentrations. Canopy Growth and its medical division Spectrum Therapeutics continue to advance a range of research initiatives aimed at furthering the understanding of – and unleashing – the full potential of cannabis.

About Canopy Growth Corporation

Canopy Growth (TSX:WEED,NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands.

For more information visit www.canopygrowth.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

CHAMPS Smoke Shop Report, or ‘CSS’, online source for the updates and innovations on the smoke shop scene. News and information are geared strictly to accessories retail channels, with distribution limited to retailers that Smoke Shop products and wholesalers.

Newsletter

Stay informed with the most up-to-date industry news to help you grow your business: subscribe to our newsletter below!




Copyright © 2021 CHAMPS Smoke Shop Report. Terms & Conditions | Privacy Policy

To Top